LOS ANGELES, Jan. 27, 2025 /PRNewswire/ -- Partillion Bioscience Corporation ("Partillion"), a life science tools company, announced the opening of pre-orders for its Nanovial Multicell Assay Antibody ...
MultiCell Technologies Inc. (OTC:MCET) acquired the rights to the Ideal BioStent resorbable coronary stent for an undisclosed amount. The buyout, via Woonsocket, Rhode Island-based MultiCell’s ...
WOONSOCKET, R.I., Sept. 27, 2012 /PRNewswire/ – MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) is pleased to announce the acceptance by the American Society for Cell Biology® (ASCB®) of ...
WOONSOCKET, R.I., July 11, 2011 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) ("MultiCell") today announced that it entered into a sponsored research agreement with ...
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional ...
Corporation gains the ability to use these assets for assay development, biomarker identification, and ADME/Tox. MultiCell Technologies entered into a worldwide, exclusive license and technology ...
MultiCell Technologies, Inc. and Living Cell Technologies Limited (LCT) have announced that the parties have entered into a joint venture to develop therapeutic liver cell applications. The ...
MultiCell bases these forward- looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results